<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0873-2159</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Pneumologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Pneumol]]></abbrev-journal-title>
<issn>0873-2159</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Pneumologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0873-21592006000600007</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Fibrose pulmonar secundária à amiodarona: A propósito de um caso clínico]]></article-title>
<article-title xml:lang="en"><![CDATA[Amiodarone induced pulmonary fibrosis: A clinical case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Marta N]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bacellar]]></surname>
<given-names><![CDATA[Patrícia]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[Helena]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tinoco]]></surname>
<given-names><![CDATA[Nélia]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A02">
<institution><![CDATA[,Hospital de São João de Deus EPE Serviço de Pneumologia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A01">
<institution><![CDATA[,Hospital de São João de Deus EPE Serviço de Medicina ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>11</month>
<year>2006</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>11</month>
<year>2006</year>
</pub-date>
<volume>12</volume>
<numero>6</numero>
<fpage>725</fpage>
<lpage>730</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0873-21592006000600007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0873-21592006000600007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0873-21592006000600007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[A amiodarona é um eficaz fármaco anti-arrítmico usado para tratar arritmias ventriculares e supra-ventriculares, mas não isento de reacções adversas. A toxicidade pulmonar é uma delas, relativamente rara (5 a 10% dos casos), e pode ser fatal. Há vários factores que aumentam a susceptibilidadade para esta toxicidade, tais como a idade avançada e a doença pulmonar preexistente. Apresentamos um caso clínico de toxicidade pulmonar induzida pela amiodarona (fibrose pulmonar) num doente do sexo masculino, de 81 anos. Estava medicado com este fármaco, desde há 5 anos, com uma dose diária de 200 mg. Após a suspensão do fármaco e tratamento com corticosteróides sistémicos, houve melhoria clínica, funcional e radiológica. Este caso clínico realça a necessidade de uma monitorização e diagnóstico precoce dos efeitos adversos do tratamento com a amiodarona e a dificuldade no seu diagnóstico, devido à inespecificidade dos sintomas, das manifestações clínicas e dos resultados dos exames complementares de diagnóstico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Amiodarone is an antiarrhytmic drug and it is used to treat supraventricular or ventricular rhythm disturbances. Nevertheless it is not free of side effects. Amiodarone-induced pulmonary toxicity is one of them and is relatively rare (5 to 10% of cases) and can be fatal. There are several cumulative factors that may enhance susceptibility to pulmonary toxicity, such as advanced age and pre-existing pulmonary dysfunction. We present a case study of amiodarone-induced toxicity (pulmonary fibrosis) in an 81-year-old man. The patient had been treated with amiodarone for five years in daily dose 200 mg/day. After withdrawing the drug and systemic corticosteroid therapy, clinical, functional and radiological improvement was observed. This case confirms the needs of a vigilant monitoring and early diagnosis of the adverse effects of amiodarone therapy, and the difficulty of diagnosing it due to the nonspecificity of symptoms, clinical findings, and test results.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Fibrose pulmonar]]></kwd>
<kwd lng="pt"><![CDATA[toxicidade da amiodarona]]></kwd>
<kwd lng="en"><![CDATA[Pulmonary fibrosis]]></kwd>
<kwd lng="en"><![CDATA[amiodarone toxicity]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p><b>Fibrose pulmonar secundária à amiodarona &#8211; A propósito de um caso clínico</b></p>      <p><b>Amiodarone induced pulmonary fibrosis &#8211; A clinical case report</b></p>      <p>&nbsp;</p>      <p><b>Marta N Silva <sup><a href="#1">1</a><a name="top1"></a></sup></b></p>      <p><b>Patrícia Bacellar <sup><a href="#1">1</a><a name="top1"></a></sup></b></p>      <p><b>Helena Martins <sup><a href="#1">1</a><a name="top1"></a></sup></b></p>      <p><b>Nélia</b><b> Tinoco <sup><a href="#2">2</a><a name="top2"></a></sup></b></p>      <p><b>Francisco Costa <sup><a href="#3">3</a><a name="top3"></a></sup></b></p>      <p>&nbsp;</p>      <p align="center"><b>Resumo</b></p>      ]]></body>
<body><![CDATA[<p align="justify">A amiodarona é um eficaz fármaco anti-arrítmico usado para    tratar arritmias ventriculares e supra-ventriculares, mas não isento de reacções    adversas. A toxicidade pulmonar é uma delas, relativamente rara (5 a 10% dos    casos), e pode ser fatal. Há vários factores que aumentam a susceptibilidadade    para esta toxicidade, tais como a idade avançada e a doença pulmonar preexistente.    Apresentamos um caso clínico de toxicidade pulmonar induzida pela amiodarona    (fibrose pulmonar) num doente do sexo masculino, de 81 anos. Estava medicado    com este fármaco, desde há 5 anos, com uma dose diária de 200 mg. Após a suspensão    do fármaco e tratamento com corticosteróides sistémicos, houve melhoria clínica,    funcional e radiológica. Este caso clínico realça a necessidade de uma monitorização    e diagnóstico precoce dos efeitos adversos do tratamento com a amiodarona e    a dificuldade no seu diagnóstico, devido à inespecificidade dos sintomas, das    manifestações clínicas e dos resultados dos exames complementares de diagnóstico.</p>     <p align="justify"><b>Palavras-chave: </b>Fibrose pulmonar, toxicidade da amiodarona.</p>      <p>&nbsp;</p>      <p align="center"><b>Abstract</b></p>      <p align="justify">Amiodarone is an antiarrhytmic drug and it is used to treat    supraventricular or ventricular rhythm disturbances. Nevertheless it is not    free of side effects. Amiodarone-induced pulmonary toxicity is one of them and    is relatively rare (5 to 10% of cases) and can be fatal. There are several cumulative    factors that may enhance susceptibility to pulmonary toxicity, such as advanced    age and pre-existing pulmonary dysfunction. We present a case study of amiodarone-induced    toxicity (pulmonary fibrosis) in an 81-year-old man. The patient had been treated    with amiodarone for five years in daily dose 200 mg/day. After withdrawing the    drug and systemic corticosteroid therapy, clinical, functional and radiological    improvement was observed. This case confirms the needs of a vigilant monitoring    and early diagnosis of the adverse effects of amiodarone therapy, and the difficulty    of diagnosing it due to the nonspecificity of symptoms, clinical findings, and    test results.</p>     <p align="justify"><b>Key-words</b><b>: </b>Pulmonary fibrosis, amiodarone toxicity.</p>      <p>&nbsp;</p>      <p>Texto completo disponível apenas em PDF.</p>     <p>Full text only available in PDF format.</p>      <p>&nbsp;</p>      ]]></body>
<body><![CDATA[<p align="center"><b>Bibliografia</b></p>      <!-- ref --><p>1. Zipes, Libby, Bonow, Braunwald. Therapy for Cardiac Arrhytmias. Braunwald&#8217;s Heart Disease, a Textbook of Cardiovascular Medicine, 7th edition; vol 1: 729-731.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000024&pid=S0873-2159200600060000700001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p>2. Mário Terra Filho. Toxicidade pulmonar pela amiodarona; Rev Soc Cardiol Estado de São Paulo 1998; vol 8 (6).</p>      <p>3. Interstitial Lung Disease, Interstitial lung disease related to specific drugs &#8211; Amiodarone pneumonitis or Amiodarone lung Schwartz, King; 4th edition, 2003; 511-515.</p>      <p>4. Lee Goldman, Dennis Ansiello. Interstitial Lung Disease. Cecil Textbook of Medicine, 22nd edition: 523-531.</p>      <p>5. Ben-Noun. Drug induced respiratory disorders: incidence, prevention and management. Drug Saf 2000; 23 (2): 143-164.</p>      <p>6. Michael Ott, Andreas Khoor, Jack Leventhal, Timothy Patrick, Charles Burger. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 2003; 123: 646-651.</p>      <p>7. Kanji Z., Sunderji R., Gink. Amiodarone induced pulmonary toxicity. Pharmacotherapy 1999; 19 (12): 1463-6.</p>      <p>8. Alonso-Fernandez, Alvarez Sala, Mediano O, Torres I, Moreno I. An Med Interna 2003; 20 (8): 419-20.</p>      <p>9. Siniakowicz RM, Narula D, Suster B, Steinberg JS. Diagnosis of amiodarone    pulmonary toxicity whith high-resolution computerized tomographic scan. J Cardiovasc    Electrophysiol 2001; 12 (4): 431-6.</p>      ]]></body>
<body><![CDATA[<p>&nbsp;</p>      <p><sup><a href="#top1">1</a><a name="1"></a></sup> Interna Complementar de Medicina    Interna</p>      <p><sup><a href="#top2">2</a><a name="2"></a></sup> Assistente Hospitalar de Pneumologia</p>      <p><sup><a href="#top3">3</a><a name="3"></a></sup> Director do Serviço de Pneumologia</p>      <p>&nbsp;</p>      <p>Hospital de São João de Deus EPE</p>     <p>Serviço de Pneumologia (Director: Dr Francisco Costa)</p>     <p>Serviço de Medicina (Directora: Drª Helena Rodrigues)</p>     <p>Apartado 31 – EC</p>     <p>4761-917 V. N. Famalicão</p>      ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p>Contacto: Marta Helena de Oliveira Novais da Silva</p>     <p>Rua Gross Umstadt, 320</p>     <p>Quinta do Geão</p>     <p>4780-373 Santo Tirso</p>      <p>&nbsp;</p>      <p>Recebido para publicação/received for publication: 06.06.02</p>     <p>Aceite para publicação/accepted for publication: 06.07.28</p>       ]]></body><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zipes]]></surname>
<given-names><![CDATA[Libby]]></given-names>
</name>
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[Braunwald]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Therapy for Cardiac Arrhytmias]]></article-title>
<source><![CDATA[Braunwald’s Heart Disease, a Textbook of Cardiovascular Medicine]]></source>
<year></year>
<volume>1</volume>
<edition>7</edition>
<page-range>729-731</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
